Published in final edited form as:

Cell Mol Life Sci. 2008 July ; 65(13): 2056–2068. doi:10.1007/s00018-008-7586-4.

ADAM Proteases: Ligand Processing and Modulation of the Notch Pathway

Anna Zolkiewska

Department of Biochemistry, Kansas State University, Manhattan, Kansas

Abstract

ADAM metalloproteases play important roles in development and disease. One of the key functions of ADAMs is the proteolytic processing of Notch receptors and their ligands. ADAM-mediated cleavage of Notch represents the first step of the regulated intramembrane proteolysis of the receptor, leading to activation of the Notch pathway. Recent reports indicate that the transmembrane Notch ligands also undergo ADAM-mediated processing in cultured cells and *in vivo*. The proteolytic processing of Notch ligands modulates the strength and duration of Notch signals, leads to generation of soluble intracellular domains of the ligands, and may support a bi-directional signaling between cells.

Keywords

Metalloprotease; Disintegrin; Proteolysis; Signaling; Notch; Delta; Ligand

1. Introduction

ADAMs (containing a disintegrin and metalloprotease) are a family of modular transmembrane proteins that mediate cell-surface proteolysis and modulate cell-cell and cell-matrix interactions [1–3]. To date, 23 different ADAMs have been identified in the human genome. A prototypical ADAM contains a secretion signal sequence at its N-terminus, followed by a pro-domain, metalloprotease, disintegrin, cysteine-rich, epidermal-growth factor (EGF)-like, transmembrane, and cytoplasmic domains. As a result of alternative mRNA splicing, soluble isoforms of several ADAMs are also produced. A related group of 19 ADAMTS and 3 ADAMTS-like proteins represent secreted soluble metalloproteases in which the transmembrane and cytoplasmic domains are replaced with a variable number of thrombospondin motifs [4,5]. Recent progress in structure determination of several ADAM domains has brought us closer to understanding the molecular mechanism of ADAM-mediated proteolytic reactions or protein-protein interactions [6–10]. Genetic and biochemical studies have generated a wealth of information on the role of ADAMs and ADAMTSs in modulating various signaling pathways and controlling cell behavior [11–14]. Proteolytic processing of Notch receptors and their ligands emerges as one of the key functions of ADAMs with important implications in development and disease.

The Notch pathway is an evolutionary conserved signaling mechanism that plays a critical role in cell fate decisions and pattern formation [15–18]. In mammals, Notch provides key signals during neural, cardiovascular, immune, liver, and kidney development. In adult organisms, the Notch pathway has been implicated in tissue regeneration and the function of stem cells [19–

21]. Not surprisingly, aberrant Notch signaling has been linked to various human diseases [22–24].

The Notch pathway is activated when one of the DSL ligands (Delta and Serrate in *Drosophila*, Lag2 in *C. elegans*), a transmembrane protein present at the surface of a signal-sending cell, binds to a Notch receptor in a signal-receiving cell. In mammals, there are five DSL ligands (Delta-like 1, 3, and 4, and Jagged 1 and 2) and four Notch receptors (Notch 1–4). During intracellular maturation, mammalian Notch receptors are cleaved at the S1 site in the extracellular domain by a furin-like protease [25]. The resulting two fragments, the extracellular domain (NECD) and the transmembrane domain (NTM), are held together by a heterodimerization (HD) domain [26]. The ligand-receptor interaction is followed by a sequential cleavage of the receptor by an ADAM protease at the S2 site in the juxtamembrane region of the extracellular domain and by presenilin-dependent γ -secretase at the S3/S4 sites in the transmembrane domain [27–30]. Cleavage by γ -secretase leads to a release of the intracellular domain of Notch (NICD) and its translocation to the nucleus. Inside the nucleus, NICD forms a complex with the CSL DNA-binding protein (CBF1 in mammals, also known as RBP-J in mouse, Suppressor of Hairless in *Drosophila*, and Lag1 in *C. elegans*) and the Mastermind/Lag3 coactivator, and activates target gene expression.

The Notch pathway is regulated by several mechanisms, including feedback regulation of receptor and ligand transcription, glycosylation, and receptor and ligand ubiquitination and endocytosis [31–34]. This review will focus on the role of ADAM proteases in modulating Notch signaling via the proteolytic processing of the Notch receptors and the DSL ligands. ADAM-mediated cleavage of Notch, an indispensable step in turning the Notch signal on, has been discussed in detail in other reviews [15–18]. Here, we will summarize the most recent advances in understanding of this reaction. Proteolytic processing of the DSL ligands and its physiological role in modulating the Notch pathway, has received considerably less attention than cleavage of Notch itself. In this review, we will discuss the following questions: Which DSL ligands are substrates for ADAM-mediated cleavage? Does the cleavage occur *in vivo*? Which ADAMs mediate the processing? How is the processing regulated? Finally, what are the physiological consequences of ligand processing?

2. ADAM-mediated cleavage of Notch

Although Notch receptors are transmembrane proteins residing at the cell surface, the active form of Notch is represented by the soluble intracellular domain of the receptor, NICD. ADAM-mediated cleavage of Notch is a necessary prerequisite for the subsequent processing by γ -secretase and the generation of NICD (Fig. 1A). Two ADAMs have been implicated in the S2 cleavage of Notch. In *Drosophila*, ADAM10 ortholog Kuzbanian is the main protease mediating Notch processing [35–38]. In mouse cells *in vitro*, ADAM17, and not ADAM10, appears to be a protease responsible for Notch cleavage [30,39]. ADAM17-deficient mice do not show, however, a "Notch phenotype" [40]. In contrast, ADAM10 deficiency leads to embryonic lethality at E9.5 and multiple malformations [41] resembling those observed in Notch1 knockout mice, in mice homozygous for a γ -secretase processing-deficient allele of Notch1, or in presenilin1/presenilin2 double knockout mice [42–44]. Thus, as proposed by Hartmann et al., different ADAMs may contribute to the S2 cleavage in a tissue-specific manner, with ADAM10 playing the major role in this process *in vivo* [41].

In flies and vertebrates, an efficient processing by ADAMs requires that Notch present in a signal-receiving cell binds *in trans* to a DSL ligand present in a signal-sending cell and that the ligand undergoes endocytosis in the signal-sending cell. Recent structural analysis of human Notch2 provides an insight into the mechanism by which ligand binding may facilitate Notch proteolysis by ADAMs [45]. Before ligand-induced activation, Notch is maintained in

a metalloprotease-resistant conformation by a conserved negative regulatory region (NRR) composed of three Lin12/Notch repeats (LNRs) and the HD domain, which contains the S2 cleavage site. Extensive interactions between LNRs and the HD domain stabilize the NRR in the autoinhibited conformation and bury the S2 site, making it inaccessible for ADAM cleavage [45]. It is clear that exposure of the S2 site requires a substantial conformational change in the NRR. Such a change could result from ligand binding followed by its endocytosis, generating a mechanical force to "peel" the protective LNR domains from the HD domain. Indeed, deletion of all three LNR modules produces a constitutively active form of Notch [45,46].

Upon ligand endocytosis, the NECD portion of Notch is internalized into the ligand-expressing cell, and it has been postulated that this transendocytosis of NECD depends on ADAM cleavage [47]. Interestingly, a recent study has demonstrated that treatment of mammalian cells with a metalloprotease inhibitor BB94 does not perturb the NECD separation and transendocytosis. The BB94 treatment does inhibit, however, the generation of NICD and diminishes Notch reporter activity [48]. Thus, in the case of a heterodimeric mammalian Notch, NECD release and transendocytosis precede and facilitate Notch cleavage by ADAMs, rather than being a consequence of such cleavage. Dissociation of the heterodimeric Notch by ligand-expressing cells may thus disengage the LNR domains from the HD domain, uncover the S2 cleavage site, and convert Notch from an ADAM-insensitive to an ADAM-sensitive substrate. Such "preparation" of Notch for ADAM cleavage is obviously possible only when Notch is a heterodimeric protein, processed at the S1 site. In flies, however, Notch is not cleaved at the S1 site, but it is still efficiently cleaved by ADAMs upon ligand binding [49], indicating that the dissociation of the NECD prior to ADAM cleavage is not always an obligatory step in receptor activation. On the other hand, the fact that ADAM activity in mammalian cells is not required for removal of NECD but it is still necessary for subsequent generation of NICD points to an important role for ADAMs in clipping the extracellular sequences of the transmembrane NTM fragment and preparing it for the γ -secretase cleavage.

The classical model of Notch activation described above implies that ADAM-mediated cleavage is an obligatory step prior to the cleavage by γ -secretase. A recent report suggests, however, that under certain conditions Notch activation may follow alternate activation mechanisms. During pancreatic acinar transdifferentiation into duct-like epithelia, a process associated with pancreatic tumorigenesis and controlled by the Notch pathway [50], Notch appears to be activated by matrix metalloproteinase 7 (MMP-7) rather than an ADAM. The MMP-7 activity is both required and sufficient for Notch-mediated transdifferentiation [51]. In COS-7 cells transfected with the full-length Notch, recombinant MMP-7 induces the cleavage of Notch by γ -secretase, nuclear translocation of NICD, and target gene expression [51]. The authors hypothesized that the secreted MMP-7, which is overexpressed in pathological conditions, could cleave Notch at the S2 site in a ligand-independent manner, but the exact cleavage site of Notch by MMP-7, has not been determined. Given the fact, however, that in the absence of a ligand the S2 site is masked by the NRR, cleavage at this site by MMP-7 seems unlikely and the mechanism of Notch activation by MMP-7 remains unclear.

3. ADAM-mediated cleavage of DSL ligands

Proteolytic processing of a Notch ligand (Fig. 1B, Fig. 1C) was reported for the first time for *Drosophila* Delta (DI) [52,53]. These ground-breaking experiments have established that DI is cleaved both in cultured cells and *in vivo* and that Kuz represents the main ADAM responsible for the cleavage [52,53]. In S2 cells transfected with DI, the extracellular fragment of DI, DI-EC, is released to culture medium. Co-transfection of the wild-type *Drosophila* ADAM10 (Kuzbanian, or Kuz) increases the abundance of DI-EC, whereas co-transfection of a dominant-negative Kuz lacking pro- and metalloprotease domains has an inhibitory effect [52]. Co-culture of DI-transfected cells with Kuz-transfected cells does not increase the cleavage of DI,

suggesting that the cleavage occurs in *cis* orientation [54]. DI-EC is detected in *kuz*^{+/-} *Drosophila* embryos, but not in *kuz*^{-/-} embryos [52]. Simultaneous detection of the extracellular and the intracellular domains of DI in early stages of embryogenesis using two different antibodies indicates that the two domains frequently distribute to different endocytic vesicles and thus must be separated during DI cleavage *in vivo* [53].

In S2 cell co-transfection experiments, two forms of DI-EC have been identified, with the molecular masses of 65 and 63 kDa. Based on the C-terminal sequences of these two species, it has been proposed that the cleavage occurs after Ala581 or Ala593, 14 or 2 amino acids, respectively, from the transmembrane domain [54]. Mutation of one or both of these two residues, however, does not prevent the cleavage [54]. More recently, a membrane-associated cleavage product of DI has been described whose N-terminal sequence begins at His577 [55]. Treatment of cells with metalloprotease inhibitors GM6001 and TAPI-1 or with Kuz RNAi [56] efficiently blocks accumulation of this product, indicating that Kuz is responsible for the cleavage of the Ala576-His577 bond. Thus, it is possible that Kuz cleaves DI at several distinct sites located in the juxtamembrane region (Fig. 2).

Drosophila genome harbors five ADAM metalloproteases: two homologs for ADAM10, Kuz and Kuzbanian-like (Kul), two homologs for ADAM12, Dmeltrin and Mmd, and a single homolog for ADAM17, DTACE [57]. Co-transfection experiments in S2 cells have established that Kuz, Kul and DTACE exhibit similar potencies of cleaving DI, whereas Dmeltrin is inactive. Serrate (Ser), the second ligand of Notch in *Drosophila*, is also cleaved by Kuz, Kul, and DTACE, but not by Dmeltrin [57]. The ability of Mmd to process DI or Ser has not been tested.

Although the amino acid sequence of the membrane-proximal region of DI is not conserved between flies and mammals, several of the mammalian DSL ligands also undergo ADAM-mediated cleavage at the juxtamembrane region of the extracellular domain (Fig. 2). Mouse Delta-like 1 (Dl1) overexpressed in N2a neuroblastoma cells, HEK293T, or COS-7 cells is constitutively cleaved by endogenous ADAMs to generate Dl1-TMIC, a transmembrane and intracellular domain fragment [58–60] and Dl1-EC, an extracellular fragment released to medium [59,60]. Similar processing has been observed for rat Dl1 and Jagged1 transfected into COS7 or CHO cells [61] and for human Jagged2 in NIH3T3 cells [58]. Furthermore, the endogenous Dl1 expressed in cultured primary mouse muscle cells (myoblasts) appears to be partially cleaved and a C-terminal fragment corresponding to Dl1-TMIC is detected when cells are stimulated to differentiate [60]. Microsomal membranes isolated from rat embryos at day E13, during a peak of the expression of Jagged1, contain both the full-length and the C-terminal fragment of Jagged1 [61]. Thus, not only is the cleavage of Jagged1 detected in cultured cells, but it may also occur *in vivo*.

To date, at least four different ADAMs have been implicated in the processing of DSL ligands in mammalian cells, namely ADAM17, ADAM10, ADAM12, and ADAM9. The cleavage of Jagged1 transfected into CHO cells is efficiently inhibited by ADAM17 inhibitor batimistat, suggesting that ADAM17 may process Jagged1 [61]. The extent of Dl1 cleavage is decreased by ~ 50% when Dl1 is overexpressed in *ADAM10*^{-/-} mouse embryonic fibroblasts (MEFs) compared to wild-type MEFs [59]. Although this result supports a role of ADAM10 in the processing of Dl1, it also suggests that other ADAMs may catalyze the Dl1 cleavage as well. Indeed, co-transfection of mouse ADAM17 or ADAM12 together with mouse Dl1 into COS-7 cells significantly enhances the cleavage of Dl1, demonstrating that these ADAMs are capable of recognizing Dl1 as a substrate [60]. Transfection of ADAM9 has a more modest effect, whereas ADAM15 is not able to process Dl1 at all. The extent of Dl1 processing is diminished by ~50% in *ADAM9/12/15*^{-/-} MEFs and in primary myoblasts treated with ADAM12 small interfering RNAs, suggesting that the endogenous ADAM12 and/or ADAM9 contribute to the

Dll1 processing. Hence, ADAM12- and ADAM9-mediated processing of mammalian Dll1 represent two novel proteolytic events, not previously seen in flies.

The cleavage site in mouse Dll1 has been identified between His535 and Met536, 10 amino acid away from the transmembrane domain [59] (Fig. 2B). Point mutations at or around the cleavage site do not have, however, any effect on the processing of Dll1 and more extensive changes in the Dll1 sequences are required to abolish the cleavage. For example, in two non-cleavable Dll1 mutants, 8 amino acids surrounding the cleavage site were replaced with Asp residues and 16 residues covering the cleavage site were deleted, respectively [59]. The insensitivity of the Dll1 processing to point mutations around the cleavage site and the lack of similarity between *Drosophila* Dl, mammalian Dll1, Jagged1 and Jagged2, which all are processed at the same juxtamembrane region, are consistent with the fact that ADAMs tend to recognize a specific structural motif in their substrates rather than a primary sequence.

Since the activation status of the Notch pathway is tightly regulated in space and time, one may expect that the proteolytic processing of Notch ligands should be subjected to a regulation as well. Indeed, although our understanding of the precise regulation of ADAM-mediated ligand cleavage is still very limited, it is obvious that the cleavage is responsive to various stimuli or manipulations. The catalytic activity of ADAM17 towards a variety of protein substrates in mammalian cells is augmented by phorbol esters [14,62], whereas activity of ADAM10 is up-regulated by calcium influx and organomercurial compounds [63]. Treatment of Jagged1-transfected CHO cells with phorbol myristate acetate increases the amount of cleaved Jagged1, consistent with ADAM17-mediated processing of Jagged1 [61]. The regulation of ADAM10-mediated cleavage of mammalian Dll1 has not been examined, but Kuz-mediated processing of *Drosophila* Dl is strongly enhanced in the presence of 50 μ M *p*-aminophenylmercuric acetate [56]. Dll1 cleavage mediated by ADAM12 is not affected by phorbol esters or calcium ionophores, but it requires high cell density and is very inefficient when few cell-cell contacts are allowed [60].

Cell-density dependence of Dll1 cleavage by ADAM12 is reminiscent of ADAM-mediated processing of Notch, which takes place only after Notch binds to a ligand on neighboring cells. Whether or not a similar scenario is true for DSL ligands and whether the ligands need to engage in the intercellular interactions with Notch in order to be processed by an ADAM is not clear. The fact that the extent of processing of Jagged1 in CHO cells or Dl in S2 cells is increased when cells are co-cultured with Notch-transfected cells suggests such a possibility [55,61]. It is also feasible, however, that proteins other than Notch bind to DSL ligands, or even to ADAMs, *in trans* and facilitate the proteolytic reaction. Homotypic interaction between Dl molecules on opposing cell surfaces have been detected using S2 cell aggregation assays [64], and similar interactions have been reported for mammalian Dll1 [65,66]. Thus, cell density dependence of ligand cleavage can be achieved through homotypic ligand-ligand interactions. Furthermore, it has been recently demonstrated that interactions between DSL ligands and extracellular matrix proteins can also stimulate ligand cleavage. For example, MAGP-2 (microfibril-associated glycoprotein-2) interacts with Jagged1 and facilitates the shedding of Jagged1 from transfected cells [67]. The shedding is inhibited by hydroxamate inhibitors BB3103 and BB94, possibly implicating an ADAM protease in the cleavage reaction. The extracellular domain of Jagged1 shed from cells is found complexed with MAGP-2, inviting a speculation that MAGP-2 may play a role in stabilizing the Jagged1 fragment after release from the cell surface. The mechanism of up-regulation of DSL ligand cleavage by neighboring cells or by extracellular matrix proteins clearly needs to be examined in more detail.

During past several years, ubiquitination, endocytosis, and endosomal sorting of DSL ligands have emerged as key regulatory mechanisms of Notch signaling. Neuralized and Mind bomb,

two E3 ubiquitin ligases that act upon DSL ligands in a signal-sending cell and promote ligand endocytosis, are indispensable for efficient Notch signaling in a signal-receiving cell [32,33]. Since ligand proteolysis segregates the Notch-binding extracellular domain from the cytoplasmic domain that interacts with the endocytic machinery, a possible link between ligand proteolysis and endocytosis is a question of a great importance. Wang and Struhl have shown that epsin, an adaptor protein that targets mono-ubiquitinated surface proteins for clathrin-mediated endocytosis, is vital for generating functional DSL ligands [68]. *Drosophila* cells that are devoid of epsin cannot send DSL signals to neighbors. Surprisingly, epsin-deficient cells have been also reported to be unable to proteolyze DI, prompting speculations that DI cleavage might occur in endocytic vesicles [68]. It has to be pointed out, however, that the engineered form of DI used in the epsin experiments contained six tandem copies of the myc epitope that were inserted after Ala576, exactly at a Kuz cleavage site. Thus, it is not clear whether the processing of the myc-tagged DI observed in epsin-positive cells was mediated by Kuz, especially since the C-terminal cleavage product was significantly larger than expected (50 kDa vs 30 kDa). Most importantly, the loss of DI proteolysis in epsin-deficient cells was observed only when Neuralized, a ubiquitin ligase for DI, was overexpressed and the majority of DI was cleared from the cell surface via clathrin-dependent and clathrin-independent endocytosis. In a different study, S2 cells were co-transfected with Neuralized and DI lacking any foreign insertions in the juxtamembrane region. In this case, Neuralized increased the extent of DI endocytosis, but a significant portion of DI still remained at the cell surface and DI processing was not changed [55]. Furthermore, when DI was transfected into a cell line that carried a temperature sensitive mutant allele of dynamin, DI proteolysis was not changed at restrictive temperatures at which there was no endocytosis [55]. Based on these results, it has been concluded that proteolysis of DI proceeds independent of endocytosis [55]. A possibility that seems consistent with the two studies discussed above is that DI proteolysis takes place both at the cell surface and in a subset of epsin-dependent endocytic vesicles, but not in other types of endocytic vesicles.

4. Consequences of DSL ligand cleavage

4.1. Down-regulation of Notch activity *in trans*

Following the cleavage by ADAMs in the juxtamembrane region, the extracellular domains of DSL ligands are released to the external compartment as soluble proteins. In worms, engineered soluble forms of DSL ligands APX-1 and LAG-2 are capable of activating Notch [69] and some naturally occurring, functional ligands (for example, DSL-1) are secreted [70]. In flies and mammals, however, soluble forms of DSL ligands either do not activate Notch or have antagonistic activities. For example, soluble forms of *Drosophila* DI bind to Notch with very weak affinities and are inactive *in vivo* [54]. In cultured mammalian cells, soluble extracellular domains of Dll1 [71–73], Dll4 [74–76], or Jagged1 [77,78] block Notch activity, as judged by Notch target gene expression. The inability of soluble DSL ligands to elicit Notch signals is consistent with the current model of Notch activation, in which membrane-tethered ligands undergoing endocytosis exert a pulling force on Notch, facilitate the cleavage at the S2 site, and make the signaling more potent [31–34]. Interestingly, immobilization of soluble ligands on a matrix [79] or clustering with antibodies [80,81] also induces Notch activation, most likely by creating a rigid scaffold that allows the generation of a mechanical force when a bound Notch cell moves away from the ligand source [31].

As physiologically relevant mechanisms for immobilization of soluble DSL ligands that are released by ADAMs have not been identified in mammals or flies, an immediate consequence of ADAM-mediated proteolysis is the clearance of functional ligands from the cell surface and down-regulation of Notch signaling in adjacent cells [54]. Two reports have demonstrated the importance of this mode of regulation of the Notch pathway *in vivo*. In the first report, the level of Kuzbanian-like, a *Drosophila* ADAM10 homolog processing DI and Ser but not Notch, was

knock-downed in the *Drosophila* wing. As a result, the amount of uncleaved Dl was elevated, leading to alterations in the directionality of Notch signaling and abnormal wing development [57].

The second study has examined the effect of deletion of the *Reck* gene in mice on the developing central nervous system (CNS) [82]. RECK (reversion-inducing cysteine-rich protein with Kazal motifs) is a glycosylphosphatidylinositol-anchored cell surface protein, specifically expressed in nestin-positive neural precursor cells (NPCs) [83,84]. Previously known to inhibit matrix metalloprotease 2 and 9 (MMP2 and MMP9) and membrane type-1 matrix metalloproteinase (MT1-MMP), RECK has emerged as a physiological inhibitor of ADAM10 [82]. In RECK-deficient embryos, Notch signaling is impaired, expression of the transcriptional targets for Notch (Hes1 and Hes5) is down-regulated, and NPCs undergo precocious differentiation [82]. This phenotype is rescued by expressing constitutively active Notch or by suppressing the endogenous ADAM10 activity with a selective ADAM10 inhibitor GI254023X or with RNA interference. In cultured cells, RECK down-regulates Dll1 shedding mediated by ADAM10, induces Notch signaling in neighboring cells, and prevents their differentiation. Overexpression of RECK in Notch-transfected cells does not appear to influence Notch signaling in a cell-autonomous manner. Thus, the defective neurogenesis in *Reck*^{-/-} mice has been attributed to excessive Dll1 shedding by ADAM10 and down-regulation of Notch activity *in trans* [82]. RECK also shows a certain degree of specificity in its inhibition of ADAMs, as it does not inhibit ADAM12-mediated Dll1 shedding [82]. Although the structural basis of the inhibition of ADAM10 activity towards Dll1 by RECK is not clear, it appears that a tight spacio-temporal control of Dll1 shedding is necessary for the CNS development.

4.2. Relief of *cis*-inhibition of Notch?

DSL ligands expressed at high levels act as antagonists of Notch present in the same cell, a cell-autonomous effect known as *cis*-inhibition [85]. This mode of action of the DSL ligands is best characterized in flies. In the developing *Drosophila* wing margins, clones of cells expressing high levels of Dl or Ser are insensitive to the Dl or Ser signals from neighboring cells. In contrast, elevated Notch signaling is detected in cells that lack both Dl and Ser [86]. Ectopic expression of Dl or Ser in neurons within developing bristle organs or in the wing interfere in a cell-autonomous manner with the ability of cells to receive Notch signals [87, 88].

Recent studies suggest a model of *cis*-inhibition of Notch in flies in which the extracellular domain of a ligand binds to the extracellular domain of a receptor in a cell-autonomous manner, the binding takes place when both the ligand and the receptor are present at the cell surface, and the *cis*-inhibitory interactions reduce the amount of receptor available for *trans*-activation. First, *cis*-inhibition by Ser requires the intact DSL domain, as mutation of five critical residues in the DSL domain to alanines abolishes the ability of Ser to *cis*-inhibit Notch [89]. Second, two mutations that severely reduce Ser endocytosis (substitution of a dileucine motif at the position 1352–1353 with alanines or deletion of amino acids 1269–1285 in the cytotail), cause accumulation of both Ser and Notch at the cell surface and have an inhibitory effect on Notch signaling *in vivo*. In contrast, adding a C-terminal endoplasmic reticulum-retention signal (KKYL) to Ser reduces *cis*-inhibition [89]. Furthermore, ectopic expression of the wild-type Neuralized, a DSL ligand ubiquitin ligase, compromises *cis*-inhibition of Notch mediated by Ser, and expression of dominant-negative Neuralized (Neur Δ RING) increases *cis*-inhibition [89]. Collectively, these results strongly suggest that *cis*-inhibitory interactions between Ser and Notch in flies involve their extracellular domains and take place at the cell surface.

Cis-inhibition of Notch by DSL ligands has been also observed in vertebrate systems. Expression of a truncated Dll1 lacking all but 13 amino acids in the intracellular domain in the

embryonic chick retinal neuroepithelium renders cells irresponsive to signals from their neighbors [90]. Overexpression of Dll1 in cultured N2a neuroblastoma cells stimulates neurite extension, increases the number of primary neurites, and decreases the rate of proliferation. Dll1-transfected N2a cells resemble cells treated with dominant-negative extracellular domain of Notch, Notch-EC [91]. Furthermore, chicken Dll1 or Ser1 cells associate in a cell-autonomous manner with mouse Notch1 when co-transfected into COS-7 or HEK293, and this interaction, similar to the *cis*-interaction in *Drosophila*, is mediated by the extracellular domains of Notch1 and Ser1 [92]. Co-expression of Dll1 or Ser1 with Notch1 in signal-receiving cells and co-culture with Dll1-transfected signal-sending cells reduces Notch-mediated HES-5 promoter activity, demonstrating that cell-autonomous ligand/receptor complexes decrease cell receptivity to Notch signals [92]. Intriguingly, Dll1/Notch1 and Ser1/Notch1 complexes that are immunoprecipitated from transfected cells do not appear to be cell surface biotinylated [92]. It has been suggested that these complexes, unlike complexes of *Drosophila* Ser and Notch, may form and reside inside the cell [92]. Consistent with this possibility is the finding that ubiquitination of *Xenopus* Delta, Xdelta1, by Mind Bomb expressed in C2C12 myogenic cells does not reduce *cis*-inhibition of Notch mediated by Xdelta1 [93]. However, if the inhibitory ligand-receptor interactions take place inside the cell, ligand overexpression and the resulting *cis*-inhibition of the receptor should be accompanied by diminished amounts of the active Notch at the cell surface. In contrast, overexpression of ligand and receptor in the same cell does not change the level of receptor at the cell surface, arguing against the intracellular localization of the ligand-receptor complexes [92,94]. The relief of *cis*-inhibition following ADAM-mediated cleavage of Dll1 (see below) further suggests that the inhibitory ligand/receptor complexes in mammalian cells, similar to the complexes in *Drosophila* cells, most likely reside at the cell surface, rather than in the intracellular compartments.

Direct *cis*-interactions between rat Dll1 or Dll3 and Notch1 are also detected using transfected NIH3T3 cells and co-immunoprecipitation assays [94]. It is particularly interesting that Dll3 does not bind to Notch1 *in trans* and is not able to activate Notch in neighboring cells but, when overexpressed in NIH3T3 cells, it efficiently inhibits Notch signaling in a cell autonomous manner [94]. However, the endogenous Dll3 has been recently found to reside in the Golgi apparatus and its role in repression of Notch activation *in vivo* has been challenged [95].

Studies utilizing human primary keratinocytes cultured *in vitro* or mice lacking Dll1 expression in the epidermis have demonstrated an important role of Dll1 and Dll1/Notch *cis* interactions in epidermal homeostasis [96,97]. In human epidermis, the highest level of Dll1 expression is observed in the basal layer, in the clusters of stem cells [96]. It appears that the high level of Dll1 has three effects: (i) blocking Notch signaling within the cluster (via *cis*-inhibition) to maintain the stem cell character, (ii) signaling to neighboring cells at the boundaries of the clusters to induce their differentiation into transit-amplifying cells that later give rise to terminally differentiated cells, and (iii) enhancing the cohesiveness of stem cell clusters and preventing intermingling with neighboring cells [65,98]. Human primary keratinocytes expressing high levels of Dll1 fail to respond to Dll1 signals from neighboring cells, consistent with their *cis*-inhibitory effect. Deletion of Dll1 in mouse embryonic or adult epidermis results in increased proliferation of keratinocytes and disturbs differentiation, a result that can be partially attributed to the abolishment of *cis*-inhibition *in vivo* [97].

If *cis*-interactions between the extracellular domains of DSL ligands and Notch receptors render the receptor non-responsive to the activation by ligands *in trans*, then what is the cell-autonomous effect of the ligand shedding by ADAMs? Intuitively, one might expect that the cleavage of a ligand should relieve *cis*-inhibition. This hypothesis has been recently tested in the following experiment. NIH3T3 cells transfected with mouse Notch1 (signal-receiving

cells) were co-cultured with Dll1-transfected CHO cells (signal-sending cells) and the activity of a Notch reporter was measured in signal-receiving cells. Co-transfection of Dll1 into signal-receiving cells decreased the Notch activity due to *cis*-inhibition by Dll1. Further co-transfection of Dll1-processing ADAM12 resulted in re-activation of a Notch reporter, whereas overexpression of the catalytically inactive mutant of ADAM12, E349Q, did not have any effect [60]. These results demonstrate that, in transfected cells, ADAM-mediated processing of Dll1 indeed increases Notch signaling in a cell-autonomous manner (Fig. 1C). Whether the proteolytic processing of the endogenous DSL ligands by ADAMs *in vivo* causes a similar relief of *cis*-inhibition of Notch remains to be determined.

4.3. Sequential DSL ligand cleavage by γ -secretase

ADAM-mediated processing represents the first step in the regulated intramembrane proteolysis (RIP) of mammalian DSL ligands. Cleavage by ADAMs is often followed by the processing of the TMIC fragment by a presenilin dependent γ -secretase. Although the localization of the γ -secretase cleavage site has not been determined, it has been proposed to involve a conserved Val residue located near the end of the transmembrane domain of several DSL ligands [59,61] (Fig. 2B). Since this position is analogous to the Val recognized by γ -secretase during the cleavage of Notch as well as several other transmembrane substrates, it seems feasible that it also represents a recognition site in the DSL ligands. Surprisingly, a transmembrane cleavage site located outside the region targeted by γ -secretase has been recently identified in *Drosophila* Dl. The processing of Dl at that site seems to be presenilin-independent and does not require a prior cleavage by ADAMs [55]. While it is not clear whether the transmembrane processing of *Drosophila* Dl occurs exclusively in this presenilin-independent manner or whether it involves, at least under certain conditions, presenilin-dependent cleavage, the processing of mammalian DSL ligands conforms to the classical sequential RIP mechanism.

The main product of the cleavage by γ -secretase is the intracellular fragment (IC) of a DSL ligand (Fig. 1D). The sequential processing by an ADAM protease and then by γ -secretase has been observed for mouse Dll1 expressed in neuroblastoma N2a cells and for human Jagged2 expressed in NIH3T3 cells [58]. The generation of the Dll1-IC or Jagged2-IC fragments is abolished when cells are treated with a γ -secretase inhibitor L-685,458 or when ligands are transfected into cells expressing a dominant-negative form of human presenilin 1 (PS1), D385A [58]. Similarly, mouse Dll1 is sequentially processed to generate Dll1-IC in *PS1*^{+/+} MEFs, but not in *PS1*^{-/-} MEFs [59]. Treatment of Dll1-expressing *PS1*^{+/+} MEFs with a γ -secretase inhibitor MW167 also abolishes formation of Dll1-IC and stabilizes the Dll1-TMIC form. By gel filtration and co-immunoprecipitation analyses, it has been demonstrated that both Dll1 and PS1 are parts of the same multimolecular complexes [59]. Two mutants of Dll1 that are resistant to ADAM-mediated processing, Dll1-Apa and Dll1-D8, do not generate the Dll1-IC fragment, demonstrating that the generation of Dll1-TMIC by ADAMs is a preliminary requirement for γ -secretase cleavage [59]. Finally, rat Jagged1 transfected into CHO cells is subject to sequential cleavage by ADAMs and γ -secretase, and expression of the dominant-negative PS1 and PS2, or treatment of cells with γ -secretase inhibitors DAPT or Compound E, results in accumulation of Jagged1-TMIC [61].

The intracellular domains of transmembrane proteins processed via RIP are frequently released from the membrane and, if they contain nuclear localization signals (NLSs), translocate to the nucleus. The NLSs fall into two distinct classes termed monopartite NLSs, containing a single cluster of basic amino acids K(R/K)X(R/K), and bipartite NLSs, comprising two basic clusters separated by a spacer, KRX₁₀₋₁₂KRXK [99]. All DSL ligands contain positively charged residues following the transmembrane domain that may function as stop transfer signals within the full length proteins but, once cleaved from the membrane, may play a role in the transport

to the nucleus. These membrane-proximal basic clusters in human, mouse, and rat Jagged1 and Jagged2, as well as in *Drosophila* D1, fully conform to the consensus sequence of the monopartite NLSs (Fig. 2B). The IC domain of Dll1 does not contain a typical NLS but it harbors the sequence RKRP that is conserved between species (Fig. 2B). These clusters of basic residues indeed seem to target DSL ligands to the nucleus. For example, when CHO cells are transfected with Δ EJagged1, a form of Jagged1 lacking a major part of the extracellular domain and mimicking an ADAM-cleaved protein, the Jagged1-IC fragment is readily produced by γ -secretase and it is retrieved in the nuclear fraction [61]. Deletion of the putative NLS in Jagged1 abolishes the nuclear localization of Jagged1-IC [61]. Similar cell fractionation studies suggested that Dll1-IC, generated from the full-length Dll1, is present in soluble fractions (cytosol and nucleus) of transfected HEK293 cells [59]. Immunofluorescence analysis of S2 cells transfected with HA epitope-tagged D1-IC or HeLa cells transfected with V5 epitope-tagged Dll1-IC has shown that the recombinant proteins are localized to the nucleus [56,59]. It has to be pointed out, however, that the immunofluorescence-based assays mentioned above utilized truncated DSL ligands and additional studies are needed to verify whether the full-length proteins, which are the physiological substrates of ADAMs and γ -secretase, give rise to similar intracellular species that translocate to the nucleus.

The nuclear localization of the soluble IC domains of DSL ligands suggests that they may regulate transcription of specific target genes. Indeed, there is accumulating evidence that the soluble IC domains serve as transcriptional co-activators. Co-transfection of HEK293 cells with mouse Dll1-IC-Gal4VP16 fusion protein and the Gal4VP16 reporter plasmid stimulates transcription ~70-fold [58]. The soluble IC domain of rat Jagged1 activates gene expression in CHO, COS7 and HEK293 cells via the transcription factor AP1 [61]. More recently, a systematic search for transcription factors capable of binding to the soluble IC domain of Dll1 has identified Smad2, Smad3, and Smad4 as Dll1 binding partners [100]. Most importantly, using a promoter-reporter plasmid that responds specifically to Smad3, it has been demonstrated that Dll1-IC enhances the transcriptional activity of Smad3 in response to stimulation of cells with transforming growth factor β (TGF β) [100]. Collectively, these findings imply a bi-directional signaling between Notch-expressing and ligand-expressing cells. In the classical view of the Notch pathway, signaling occurs from ligand-expressing to Notch-expressing cells. However, sequential proteolysis of the ligands which is initiated by the interactions with Notch-expressing cells and which results in the release of the ligand's intracellular domain and its translocation to the nucleus suggests that, at least in some systems, signaling may also occur in the opposite direction. ADAM-mediated cleavage of DSL ligands, the first and obligatory step in the sequential ligand processing, may thus represent a rate-limiting step in the activation of signaling in ligand-expressing cells.

Finally, it is also possible that signaling by certain DSL ligands requires cleavage by ADAMs, but it does not require processing by γ -secretase. Dll1 and Jagged1, two ligands that are processed by ADAMs, as well as Dll4, contain a consensus PDZ-binding motif, X-T/S/Y-X-V/L/I, at their C-termini (Fig. 2B). The PDZ-binding motif of Dll1 interacts with Activin receptor interacting protein 1 (Acvrin1) [101], disc large homolog 1 (Dlg1) [66], and MAGI1 [102], members of the membrane-associated guanylate kinase (MAGUK) family. In zebrafish, DeltaC and DeltaD interact with MAGI1, MAGI2, and MAGI3 [103]. Furthermore, Dll1 binds through its PDZ-binding domain to an adaptor protein syntenin and this interaction is important in Dll1-induced cell cohesiveness [98]. The identities of proteins interacting with the PDZ-binding motif of Jagged1 are not known, but this motif is necessary for Jagged1 to induce transformation of rat kidney epithelial cells and to change the profile of gene expression [104]. Interestingly, Jagged1 TMIC, lacking the extracellular domain and resembling the product of ADAM-mediated cleavage of Jagged1, does not cause cell transformation, despite the presence of the intact PDZ-binding motif [104]. Therefore, one may speculate that shedding

of the extracellular domain of the DSL ligands by ADAMs could abolish signaling events that are mediated by PDZ-binding motifs present in the ligand cytotails.

5. Conclusions

While the proteolytic processing of Notch receptors by ADAMs has been extensively studied and its role in activation of the Notch pathway is becoming more clear, the role and mechanism of ADAM-mediated ligand proteolysis are less understood. Although ligand cleavage is without any doubt less prevalent than the cleavage of the receptors, the proteolytic processing of DSL ligands modulates the strength and duration of Notch signals and leads to the generation of soluble ligand intracellular domains in ligand-expressing cells. Therefore, the proteolytic processing of DSL ligands as a mechanism of modulation of the Notch pathway deserves more attention. Future biochemical and genetic approaches should elucidate the mechanism and regulation of the ADAM-mediated ligand cleavage. For example, one of the invaluable tools in determination of the physiological significance of ligand cleavage would be the generation of transgenic mouse models in which wild type DSL ligands are replaced with their non-cleavable mutant forms. Since ADAM proteases are frequently de-regulated in many pathological conditions including cancer, an altered processing of Notch receptors and their ligands should be taken into consideration when studying ADAMs-related diseases.

Acknowledgments

This work was supported by NIH grant GM065528. This is contribution 08-192-J from the Kansas Agricultural Experiment Station.

References

1. Blobel CP. ADAMs: key components in EGFR signalling and development. *Nat. Rev. Mol. Cell Biol* 2005;6:32–43. [PubMed: 15688065]
2. Huovila AP, Turner AJ, Peltto-Huikko M, Karkkainen I, Ortiz RM. Shedding light on ADAM metalloproteinases. *Trends Biochem. Sci* 2005;30:413–422. [PubMed: 15949939]
3. Seals DF, Courtneidge SA. The ADAMs family of metalloproteinases: multidomain proteins with multiple functions. *Genes Dev* 2003;17:7–30. [PubMed: 12514095]
4. Apte SS. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. *Int. J. Biochem. Cell Biol* 2004;36:981–985. [PubMed: 15094112]
5. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. *Biochem. J* 2005;386:15–27. [PubMed: 15554875]
6. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for Ephrin cleavage in trans. *Cell* 2005;123:291–304. [PubMed: 16239146]
7. Takeda S, Igarashi T, Mori H, Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. *EMBO J* 2006;25:2388–2396. [PubMed: 16688218]
8. Igarashi T, Araki S, Mori H, Takeda S. Crystal structures of catrocollastatin/VAP2B reveal a dynamic, modular architecture of ADAM/adamalsin/reprolysin family proteins. *FEBS Letters* 2007;581:2416–2422. [PubMed: 17485084]
9. Gerhardt S, Hassall G, Hawtin P, McCall E, Flavell L, Minshall C, Hargreaves D, Ting A, Pauptit RA, Parker AE, Abbott WM. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. *J. Mol. Biol* 2007;373:891–902. [PubMed: 17897672]
10. Orth P, Reichert P, Wang W, Prosser WW, Yarosh-Tomaine T, Hammond G, Ingram, RN, Xiao L, Mirza UA, Zou J, Strickland C, Taremi SS, Le HV, Madison V. Crystal structure of the catalytic domain of human ADAM33. *J. Mol. Biol* 2004;335:129–137. [PubMed: 14659745]
11. Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. *Cancer Metastasis Rev* 2006;25:57–68. [PubMed: 16680572]

12. White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. *Curr. Opin. Cell Biol* 2003;15:598–606. [PubMed: 14519395]
13. Horiuchi K, Zhou HM, Kelly K, Manova K, Blobel CP. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins $\beta 1$ and $\beta 2$. *Dev. Biol* 2005;283:459–471. [PubMed: 15936750]
14. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, Toyama Y, Hartmann D, Saftig P, Blobel CP. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. *Mol. Biol. Cell* 2007;18:176–188. [PubMed: 17079736]
15. Fiuza UM, Arias AM. Cell and molecular biology of Notch. *J. Endocrinol* 2007;194:459–474. [PubMed: 17761886]
16. Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S. Crossing paths with Notch in the hyper-network. *Curr. Opin. Cell Biol* 2007;19:166–175. [PubMed: 17317139]
17. Bray SJ. Notch signalling: a simple pathway becomes complex. *Nat. Rev. Mol. Cell Biol* 2006;7:678–689. [PubMed: 16921404]
18. Lai EC. Notch signaling: control of cell communication and cell fate. *Development* 2004;131:965–973. [PubMed: 14973298]
19. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: Turning over new leaves. *Cell* 2007;128:445–458. [PubMed: 17289566]
20. Carlson ME, Conboy IM. Regulating the Notch pathway in embryonic, adult and old stem cells. *Curr. Opin. Pharmacol* 2007;7:303–309. [PubMed: 17475556]
21. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoepfner DJ, Ravin R, Poser SW, Rueger MA, Bae SK, Kittappa R, McKay RD. Notch signalling regulates stem cell numbers *in vitro* and *in vivo*. *Nature* 2006;442:823–826. [PubMed: 16799564]
22. Miele L, Golde T, Osborne B. Notch signaling in cancer. *Curr. Mol. Med* 2006;6:905–918. [PubMed: 17168741]
23. Louvi A, Arboleda-Velasquez JF, Artavanis-Tsakonas S. CADASIL: a critical look at a Notch disease. *Dev. Neurosci* 2006;28:5–12. [PubMed: 16508299]
24. Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease. *Semin. Cancer Biol* 2004;14:320–328. [PubMed: 15288257]
25. Logeat F, Bessia C, Brou C, LeBail O, Jarriault S, Seidah NG, Israel A. The Notch1 receptor is cleaved constitutively by a furin-like convertase. *Proc. Natl. Acad. Sci. U. S. A* 1998;95:8108–8112. [PubMed: 9653148]
26. Sanchez-Irizarry C, Carpenter AC, Weng AP, Pear WS, Aster JC, Blacklow SC. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. *Mol. Cell. Biol* 2004;24:9265–9273. [PubMed: 15485896]
27. Wolfe MS, Kopan R. Intramembrane proteolysis: Theme and variations. *Science* 2004;305:1119–1123. [PubMed: 15326347]
28. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature* 1998;393:382–386. [PubMed: 9620803]
29. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent γ -secretase-like protease mediates release of Notch intracellular domain. *Nature* 1999;398:518–522. [PubMed: 10206645]
30. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R. A ligand-induced extracellular cleavage regulates γ -secretase-like proteolytic activation of Notch1. *Mol. Cell* 2000;5:197–206. [PubMed: 10882062]
31. Nichols JT, Miyamoto A, Weinmaster G. Notch signaling - constantly on the move. *Traffic* 2007;8:959–969. [PubMed: 17547700]
32. Le Borgne R. Regulation of Notch signalling by endocytosis and endosomal sorting. *Curr. Opin. Cell Biol* 2006;18:213–222. [PubMed: 16488590]
33. Chitnis A. Why is Delta endocytosis required for effective activation of Notch? *Dev. Dyn* 2006;235:886–894. [PubMed: 16425217]

34. Schweisguth F. Regulation of Notch signaling activity. *Curr. Biol* 2004;14:R129–R138. [PubMed: 14986688]
35. Rooke J, Pan D, Xu T, Rubin GM. KUZ, a conserved metalloprotease-disintegrin protein with two roles in *Drosophila* neurogenesis. *Science* 1996;273:1227–1231. [PubMed: 8703057]
36. Pan D, Rubin GM. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during *Drosophila* and vertebrate neurogenesis. *Cell* 1997;90:271–280. [PubMed: 9244301]
37. Sotillos S, Roch F, Campuzano S. The metalloprotease-disintegrin Kuzbanian participates in Notch activation during growth and patterning of *Drosophila* imaginal discs. *Development* 1997;124:4769–4779. [PubMed: 9428413]
38. Lieber T, Kidd S, Young MW. *kuzbanian*-mediated cleavage of *Drosophila* Notch. *Genes Dev* 2002;16:209–221. [PubMed: 11799064]
39. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. *Mol. Cell* 2000;5:207–216. [PubMed: 10882063]
40. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA. An essential role for ectodomain shedding in mammalian development. *Science* 1998;282:1281–1284. [PubMed: 9812885]
41. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena IA, von Figura K, Saftig P. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. *Hum. Mol. Genet* 2002;11:2615–2624. [PubMed: 12354787]
42. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T. Notch signaling is essential for vascular morphogenesis in mice. *Genes Dev* 2000;14:1343–1352. [PubMed: 10837027]
43. Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, Kopan R. Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. *Nature* 2000;405:966–970. [PubMed: 10879540]
44. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, de Strooper B. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. *Proc. Natl. Acad. Sci. U. S. A* 1999;96:11872–11877. [PubMed: 10518543]
45. Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC. Structural basis for autoinhibition of Notch. *Nat. Struct. Mol. Biol* 2007;14:295–300. [PubMed: 17401372]
46. Lieber T, Kidd S, Alcamo E, Corbin V, Young MW. Antineurogenic phenotypes induced by truncated Notch proteins indicate a role in signal transduction and may point to a novel function for Notch in nuclei. *Genes Dev* 1993;7:1949–1965. [PubMed: 8406001]
47. Parks AL, Klueg KM, Stout JR, Muskavitch MA. Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. *Development* 2000;127:1373–1385. [PubMed: 10704384]
48. Nichols JT, Miyamoto A, Olsen SL, D'Souza B, Yao C, Weinmaster G. DSL ligand endocytosis physically dissociates Notch1 heterodimers before activating proteolysis can occur. *J. Cell Biol* 2007;176:445–458. [PubMed: 17296795]
49. Kidd S, Lieber T. Furin cleavage is not a requirement for *Drosophila* Notch function. *Mech. Dev* 2002;115:41–51. [PubMed: 12049766]
50. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM, Leach SD. Notch mediates TGF α -induced changes in epithelial differentiation during pancreatic tumorigenesis. *Cancer Cell* 2003;3:565–576. [PubMed: 12842085]
51. Sawey ET, Johnson JA, Crawford HC. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. *Proc. Natl. Acad. Sci. U. S. A* 2007;104:19327–19332. [PubMed: 18042722]
52. Qi H, Rand MD, Wu X, Sestan N, Wang W, Rakic P, Xu T, Artavanis-Tsakonas S. Processing of the Notch ligand Delta by the metalloprotease Kuzbanian. *Science* 1999;283:91–94. [PubMed: 9872749]

53. Klueg KM, Parody TR, Muskavitch MAT. Complex proteolytic processing acts on Delta, a transmembrane ligand for Notch, during *Drosophila* Development. *Mol. Biol. Cell* 1998;9:1709–1723. [PubMed: 9658166]
54. Mishra-Gorur K, Rand MD, Perez-Villamil B, Artavanis-Tsakonas S. Down-regulation of Delta by proteolytic processing. *J. Cell Biol* 2002;159:313–324. [PubMed: 12403816]
55. Delwig A, Bland C, Beem-Miller M, Kimberly P, Rand MD. Endocytosis-independent mechanisms of Delta ligand proteolysis. *Exp. Cell Res* 2006;312:1345–1360. [PubMed: 16487968]
56. Bland CE, Kimberly P, Rand MD. Notch-induced proteolysis and nuclear localization of the Delta ligand. *J. Biol. Chem* 2003;278:13607–13610. [PubMed: 12591935]
57. Sapir A, Assa-Kunik E, Tsruya R, Schejter E, Shilo BZ. Unidirectional Notch signaling depends on continuous cleavage of Delta. *Development* 2005;132:123–132. [PubMed: 15576412]
58. Ikeuchi T, Sisodia SS. The Notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent "γ-secretase" cleavage. *J. Biol. Chem* 2003;278:7751–7754. [PubMed: 12551931]
59. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, Logeat F. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and γ-secretase. *Proc. Natl. Acad. Sci. U. S. A* 2003;100:7638–7643. [PubMed: 12794186]
60. Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A. Proteolytic processing of Delta-like 1 by ADAM proteases. *J. Biol. Chem* 2007;282:436–444. [PubMed: 17107962]
61. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. *J. Biol. Chem* 2003;278:34427–34437. [PubMed: 12826675]
62. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. *J. Cell Biol* 2004;164:769–779. [PubMed: 14993236]
63. Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, Raines EW, Dunbar AJ, Dempsey PJ. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-Aminophenylmercuric acetate and extracellular calcium influx. *J. Biol. Chem* 2005;280:1826–1837. [PubMed: 15507448]
64. Klueg KM, Muskavitch MA. Ligand-receptor interactions and trans-endocytosis of Delta, Serrate and Notch: members of the Notch signalling pathway in *Drosophila*. *J. Cell Sci* 1999;112:3289–3297. [PubMed: 10504334]
65. Lowell S, Watt FM. Delta regulates keratinocyte spreading and motility independently of differentiation. *Mech. Dev* 2001;107:133–140. [PubMed: 11520669]
66. Six EM, Ndiaye D, Sauer G, Laabi Y, Athman R, Cumano A, Brou C, Israel A, Logeat F. The Notch ligand Delta1 recruits Dlg1 at cell-cell contacts and regulates cell migration. *J. Biol. Chem* 2004;279:55818–55826. [PubMed: 15485825]
67. Nehring LC, Miyamoto A, Hein PW, Weinmaster G, Shipley JM. The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface. *J. Biol. Chem* 2005;280:20349–20355. [PubMed: 15788413]
68. Wang W, Struhl G. *Drosophila* Epsin mediates a select endocytic pathway that DSL ligands must enter to activate Notch. *Development* 2004;131:5367–5380. [PubMed: 15469974]
69. Fitzgerald K, Greenwald I. Interchangeability of *Caenorhabditis elegans* DSL proteins and intrinsic signalling activity of their extracellular domains *in vivo*. *Development* 1995;121:4275–4282. [PubMed: 8575327]
70. Chen N, Greenwald I. The lateral signal for LIN-12/Notch in *C. elegans* vulval development comprises redundant secreted and transmembrane DSL proteins. *Dev. Cell* 2004;6:183–192. [PubMed: 14960273]
71. Hallahan AR, Pritchard JJ, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM. The SmoA1 mouse model reveals that Notch signaling is critical for the growth and survival of Sonic Hedgehog-induced medulloblastomas. *Cancer Res* 2004;64:7794–7800. [PubMed: 15520185]
72. Salama-Cohen P, Arevalo MA, Meier J, Grantyn R, Rodriguez-Tebar A. NGF controls dendrite development in hippocampal neurons by binding to p75NTR and modulating the cellular targets of Notch. *Mol. Biol. Cell* 2005;16:339–347. [PubMed: 15496460]

73. Trifonova R, Small D, Kacer D, Kovalenko D, Kolev V, Mandinova A, Soldi R, Liaw L, Prudovsky I, Maciag T. The non-transmembrane form of Delta1, but not of Jagged1, induces normal migratory behavior accompanied by fibroblast growth factor receptor 1-dependent transformation. *J. Biol. Chem* 2004;279:13285–13288. [PubMed: 14769803]
74. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. *Proc. Natl. Acad. of Sci* 2007;104:3219–3224. [PubMed: 17296940]
75. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Chieh Lin H, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. *Nature* 2006;444:1032–1037. [PubMed: 17183313]
76. Scehnet JS, Jiang W, RamKumar S, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. *Blood* 2007;109:4753–4760. [PubMed: 17311993]
77. Small D, Kovalenko D, Kacer D, Liaw L, Landriscina M, Di Serio C, Prudovsky I, Maciag T. Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype. *J. Biol. Chem* 2001;276:32022–32030. [PubMed: 11427524]
78. Nikopoulos GN, Duarte M, Kubu CJ, Bellum S, Friesel R, Maciag T, Prudovsky I, Verdi JM. Soluble Jagged1 attenuates lateral inhibition allowing for the clonal expansion of neural crest stem cells. *Stem Cells* 2007;25:3133–3142. [PubMed: 17761753]
79. Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID. Immobilization of Notch ligand, Delta-1, is required for induction of Notch signaling. *J. Cell Sci* 2000;113:4313–4318. [PubMed: 11069775]
80. Morrison SJ, Perez SE, Qiao Z, Verdi JM, Hicks C, Weinmaster G, Anderson DJ. Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. *Cell* 2000;101:499–510. [PubMed: 10850492]
81. Hicks C, Ladi E, Lindsell C, Hsieh JJ, Hayward SD, Collazo A, Weinmaster G. A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling. *J. Neurosci. Res* 2002;68:655–667. [PubMed: 12111827]
82. Muraguchi T, Takegami Y, Ohtsuka T, Kitajima S, Chandana EP, Omura A, Miki T, Takahashi R, Matsumoto N, Ludwig A, Noda M, Takahashi C. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. *Nat. Neurosci* 2007;10:838–845. [PubMed: 17558399]
83. Noda M, Takahashi C. Recklessness as a hallmark of aggressive cancer. *Cancer Sci* 2007;98:1659–1665. [PubMed: 17725805]
84. Clark JC, Thomas DM, Choong PF, Dass CR. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. *Cancer Metastasis Rev* 2007;26:675–683. [PubMed: 17828469]
85. Katsube K, Sakamoto K. Notch in vertebrates - molecular aspects of the signal. *Int. J. Dev. Biol* 2005;49:369–374. [PubMed: 15906253]
86. Micchelli CA, Rulifson EJ, Blair SS. The function and regulation of cut expression on the wing margin of *Drosophila*: Notch, Wingless and a dominant negative role for Delta and Serrate. *Development* 1997;124:1485–1495. [PubMed: 9108365]
87. Jacobsen TL, Brennan K, Arias AM, Muskavitch MA. *Cis*-interactions between Delta and Notch modulate neurogenic signalling in *Drosophila*. *Development* 1998;125:4531–4540. [PubMed: 9778511]
88. Klein T, Brennan K, Arias AM. An intrinsic dominant negative activity of Serrate that is modulated during wing development in *Drosophila*. *Dev. Biol* 1997;189:123–134. [PubMed: 9281342]
89. Glittenberg M, Pitsouli C, Garvey C, Delidakis C, Bray S. Role of conserved intracellular motifs in Serrate signalling, *cis*-inhibition and endocytosis. *EMBO J* 2006;25:4697–4706. [PubMed: 17006545]
90. Henrique D, Hirsinger E, Adam J, Le R, I, Pourquie O, Ish-Horowicz D, Lewis J. Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. *Curr. Biol* 1997;7:661–670. [PubMed: 9285721]

91. Franklin JL, Berechid BE, Cutting FB, Presente A, Chambers CB, Foltz DR, Ferreira A, Nye JS. Autonomous and non-autonomous regulation of mammalian neurite development by Notch1 and Delta1. *Curr. Biol* 1999;9:1448–1457. [PubMed: 10607588]
92. Sakamoto K, Ohara O, Takagi M, Takeda S, Katsube K. Intracellular cell-autonomous association of Notch and its ligands: a novel mechanism of Notch signal modification. *Dev. Biol* 2002;241:313–326. [PubMed: 11784114]
93. Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, Maust D, Yeo SY, Lorick K, Wright GJ, Ariza-McNaughton L, Weissman AM, Lewis J, Chandrasekharappa SC, Chitnis AB. Mind Bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. *Dev. Cell* 2003;4:67–82. [PubMed: 12530964]
94. Ladi E, Nichols JT, Ge W, Miyamoto A, Yao C, Yang LT, Boulter J, Sun YE, Kintner C, Weinmaster G. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. *J. Cell Biol* 2005;170:983–992. [PubMed: 16144902]
95. Schuster-Gossler K, Cordes R, Gossler A. Premature myogenic differentiation and depletion of progenitor cells cause severe muscle hypotrophy in Delta1 mutants. *Proc. Natl. Acad. Sci. U. S. A* 2007;104:537–542. [PubMed: 17194759]
96. Lowell S, Jones P, Le RI, Dunne J, Watt FM. Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters. *Curr. Biol* 2000;10:491–500. [PubMed: 10801437]
97. Estrach S, Cordes R, Hozumi K, Gossler A, Watt FM. Role of the Notch ligand Delta1 in embryonic and adult mouse epidermis. *J. Invest. Dermatol.* 2007in press
98. Estrach S, Legg J, Watt FM. Syntenin mediates Delta1-induced cohesiveness of epidermal stem cells in culture. *J. Cell Sci* 2007;120:2944–2952. [PubMed: 17666427]
99. Dingwall C, Laskey RA. Nuclear targeting sequences - a consensus? *Trends Biochem. Sci* 1991;16:478–481. [PubMed: 1664152]
100. Hiratochi M, Nagase H, Kuramochi Y, Koh CS, Ohkawara T, Nakayama K. The Delta intracellular domain mediates TGF- β /Activin signaling through binding to Smads and has an important bi-directional function in the Notch-Delta signaling pathway. *Nucleic Acids Res* 2007;35:912–922. [PubMed: 17251195]
101. Pfister S, Przemeck GKH, Gerber JK, Beckers J, Adamski J, de Angelis MH. Interaction of the MAGUK family member Acvrin1 and the cytoplasmic domain of the Notch ligand Delta1. *J. Mol. Biol* 2003;333:229–235. [PubMed: 14529612]
102. Mizuhara E, Nakatani T, Minaki Y, Sakamoto Y, Ono Y, Takai Y. MAGI1 recruits Dll1 to cadherin-based adherens junctions and stabilizes it on the cell surface. *J. Biol. Chem* 2005;280:26499–26507. [PubMed: 15908431]
103. Wright GJ, Leslie JD, Ariza-McNaughton L, Lewis J. Delta proteins and MAGI proteins: an interaction of Notch ligands with intracellular scaffolding molecules and its significance for zebrafish development. *Development* 2004;131:5659–5669. [PubMed: 15509766]
104. Ascano JM, Beverly LJ, Capobianco AJ. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. *J. Biol. Chem* 2003;278:8771–8779. [PubMed: 12496248]

Figure 1.

Different modes of ADAM modulation of the Notch pathway. A, Ligand binding induces Notch cleavage by an ADAM protease at the S2 site, followed by γ -secretase cleavage at the S3/S4 site and release of the NICD from the membrane in a signal-receiving cell. B, Ligand shedding by an ADAM in a signal-sending cell down-regulates Notch signaling in a signal-receiving cell. C, Ligand shedding by an ADAM relieves *cis*-inhibition of Notch and makes Notch available for interactions with ligands *in trans*. D, After ADAM cleavage, the transmembrane fragment of the ligand is processed by γ -secretase, and the intracellular domain released from the membrane may act as a signaling molecule.

Figure 2.

A, Schematic diagram of Dll1, one of the mammalian DSL ligands. The DSL Notch-interacting domain (the globular part) and 9 EGF-like repeats are indicated in the extracellular domain, a potential NLS motif is shown in the intracellular domain. The sites of processing by ADAM proteases and by γ -secretase are indicated by red and cyan arrows, respectively. B, Comparison of the amino acid sequences of the juxtamembrane, transmembrane, and intracellular regions of *Drosophila* and mammalian DSL ligands. dDl and dSer are Delta and Serrate; human, mouse, and rat Dll1, Dll3, Dll4, Jagged1 and Jagged2 are also shown. The reported ADAM cleavage sites in dDl and in mDl11 are indicated in red. Val residues in the transmembrane domains close to the border with the intracellular domains and representing potential cleavage

sites by presenilin-dependent γ -secretase are shown in cyan. Notice that the ligands known to be processed by ADAMs, dDl, Dll1, Jagged1 and Jagged2, contain putative NLS sites, shown in purple.